RT Journal Article
SR Electronic
T1 Framework for rational donor selection in fecal microbiota transplant clinical trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19000307
DO 10.1101/19000307
A1 Duvallet, Claire
A1 Zellmer, Caroline
A1 Panchal, Pratik
A1 Budree, Shrish
A1 Osman, Majdi
A1 Alm, Eric
YR 2019
UL http://medrxiv.org/content/early/2019/09/26/19000307.abstract
AB Early clinical successes are driving enthusiasm for fecal microbiota transplantation (FMT), the transfer of healthy gut bacteria through whole stool, as emerging research is linking the microbiome to many different diseases. However, preliminary trials have yielded mixed results and suggest that heterogeneity in donor stool may play a role in patient response. Thus, clinical trials may fail because an ineffective donor was chosen rather than because FMT is not appropriate for the indication. Here, we describe a conceptual framework to guide rational donor selection to increase the likelihood that FMT clinical trials will succeed. We argue that the mechanism by which the microbiome is hypothesized to be associated with a given indication should inform how healthy donors are selected for FMT trials, categorizing these mechanisms into four disease models and presenting associated donor selection strategies. We next walk through examples based on previously published FMT trials and ongoing investigations to illustrate how donor selection might occur in practice. Finally, we show that typical FMT trials are not powered to discover individual taxa mediating patient responses, suggesting that clinicians should develop targeted hypotheses for retrospective analyses and design their clinical trials accordingly. Moving forward, developing and applying novel clinical trial design methodologies like rational donor selection will be necessary to ensure that FMT successfully translates into clinical impact.Competing Interest StatementE.A. is co-founder of Finch Therapeutics and is on the Board of Directors of OpenBiome. C.Z, P.P, S.B, and M.O. are employed by OpenBiome. These commercial sources of funding do not alter our adherence to PLOS ONE policies on sharing data and materials.Funding StatementC.D. acknowledges funding from the Siebel Scholars Program.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesCode to reproduce all of these analyses and figures can be found at https://github.com/cduvallet/donor-selection/. Data were downloaded from original sources as described in the Methods section.https://github.com/cduvallet/donor-selection/